Novel medical function of cucurbitacin

A cucurbitacin and medical technology, applied in the field of medicine, can solve the problems of patients with loss of language function, leukopenia, etc.

Inactive Publication Date: 2007-10-31
SHENYANG PHARMA UNIVERSITY +1
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment methods for laryngeal cancer are mainly radiation therapy or surgery. Surgery often leads to loss of speech function, while radiation therapy can cause leukopenia. In addition, if

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel medical function of cucurbitacin
  • Novel medical function of cucurbitacin
  • Novel medical function of cucurbitacin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Cucurbitacin B (CuB, the purity determined by HPLC area normalization method is greater than 99%) in vitro anti-human laryngeal carcinoma cells

[0013] In vitro test (MTT)

[0014] method:

[0015] 1. Human laryngeal cancer cell Hep-2 was cultured with RPMI1640 medium containing 10% fetal bovine serum at 37°C and 5% CO 2 In the incubator, subculture once every 3-4 days. Cells in the logarithmic growth phase were selected for the experiment.

[0016] 2. Digest the adherent cells with 0.25% trypsin (containing EDTA 1mM / L) and suspend them in the culture medium to adjust the cell concentration to 2.5×10 4 / mL, inoculate 100 μL per well on a 96-well plate, with 3 replicate wells in each well. Only culture solution was added to blank control wells.

[0017] 3. After culturing for 18-24 hours and waiting for the cells to adhere to the wall, add different concentrations of drugs (0.5 μL) into groups, and the other group is the control group (without adding drugs).

[00...

Embodiment 2

[0023] Pharmacodynamic study of cucurbitacin B (CuB, purity greater than 99% determined by HPLC area normalization method) against human laryngeal cancer in vivo

[0024] method:

[0025] 1. Human laryngeal cancer cell Hep-2 was cultured with RPMI1640 medium containing 10% fetal bovine serum at 37°C and 5% CO 2 In the incubator, subculture once every 3-4 days. Cells in the logarithmic growth phase were selected for the experiment.

[0026] 2. Digest adherent cells with 0.25% trypsin (containing EDTA 1mM / L) and suspend in normal saline to adjust the cell concentration to 2.5×10 7 / mL.

[0027] 3. 40 18-20 g nude mice (BALB / C, 5-6 weeks, female, purchased from the Institute of Experimental Animals, Chinese Academy of Medical Sciences, Chinese Union Medical University) were inoculated with 5×10 cells in the right armpit 6 / only, when the tumor grows to be larger than 100mm 3 At the same time, they were randomly divided into 4 groups, respectively negative control group (0.9...

Embodiment 3

[0034] Crude extract-cucurbitacin and cucurbitacin E (the purity determined by HPLC area normalization method is greater than 95%)

[0035] Pharmacodynamic study of anti-human laryngeal carcinoma in vivo

[0036] Refer to the method of "Example 2"

[0037] 18 nude mice of 18-20 grams, inoculated with 5×10 cells in the right armpit 6 / only, when the tumor grows to be larger than 100mm 3At the same time, they were randomly divided into 3 groups, which were negative control group (0.9% sodium chloride, 0.2ml / day). kg·day), cucurbitacin E group (emulsion, intravenous injection, 200 μg / kg·day), continuous administration for 14 days. The animals were sacrificed within 24 hours after the last administration, and the tumors were weighed to calculate the tumor inhibition rate. Results The tumor inhibition rates of the cucurbitacin group and the cucurbitacin E group were 39.2% and 51.6% respectively; compared with the normal control group, the body weight and white blood cells of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new usage of cucurbitacin (Cucurbitacins) in medicinal technique domain, which is characterized by the following: using cucurbitacin and medicinal component to treat laryngocarcinoma and increase quantity of leukocyte; preparing to multiple agent type such as tablet, powder medicine, capsule, granula, oral liquid, injection and so on with the cucurbitacin or medicinal component; proceeding independent give drug or combined treatment; using to leucopenia because of radiotheraphy of tumor patient; counting the give drug dosage of cucurbitacin with total cucurbitacin; giving the drug to mouse with 0. 001mg/kg-1mg/kg; giving to adult with 0. 1mg-5mg/day.

Description

Technical field: [0001] The invention belongs to the technical field of medicine and relates to a new application of known substances cucurbitacins. Specifically, it refers to the new application of cucurbitacin and its pharmaceutical composition in treating laryngeal cancer and improving the white blood cell count of radiation therapy patients. Background technique: [0002] Cucurbitacins belong to a class of tetracyclic triterpenoids with a 19-methyl group appearing at the C-9 position. They are mainly distributed in Cucurbitaceae plants. It is also found in higher plants such as wood family and some large fungi. Qiu Minghua, a researcher at the Kunming Institute of Botany, Chinese Academy of Sciences, led scientific and technical personnel to study 229 almost all cucurbitacin compounds on the basis of the discovery of a series of new types of cucurbitacin compounds, and proposed a new structural classification model, which was reconstructed from the previous five structu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/575A61K9/06A61K9/08A61K9/10A61K9/14A61K9/16A61K9/20A61K9/48A61K9/70A61P35/00A61P7/00
Inventor 邓意辉张美霞
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap